Latest Articles
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com UK
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com UK
Published: Aug. 1, 2026, 6:38 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology
Published: July 31, 2026, 8:06 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive
Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com
Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork
Published: July 31, 2026, 2:37 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com
Published: July 31, 2026, 2:37 p.m.
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com Australia
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com Australia
Published: July 31, 2026, 11:35 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - Medical Professionals Reference
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial Medical Professionals Reference
Published: July 31, 2026, 4 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - empr.com
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial empr.com
Published: July 31, 2026, 4 a.m.
Link copied to clipboard!